Advertisement

Incidence of osteonecrosis of the jaw in Japanese osteoporosis patients taking minodronic acid

  • Akira TaguchiEmail author
  • Yukari Uemura
  • Takumi Imai
  • Shiro Tanaka
  • Hiroaki Ohta
  • Toshitaka Nakamura
  • Hajime Orimo
  • Toshitsugu Sugimoto
  • Satoshi Soen
  • Masataka Shiraki
  • Adequate Treatment of Osteoporosis (A-TOP) research group
Original Article
  • 23 Downloads

Abstract

Osteonecrosis of the jaw (ONJ) associated with bisphosphonate therapy is a rare but severe side effect in osteoporosis patients. Recently, the number of osteoporosis patients with ONJ has dramatically increased in Japan. This has contributed to an increase in the number of patients avoiding extractions. However, there has been no prospective study providing definitive incidence data for ONJ in Japanese patients. The purpose of this study was to elucidate the true as well as suspected incidence of ONJ. A total of 3229 subjects (1612 subjects in the minodronic acid group and 1617 subjects in the raloxifene group) in the Japanese Osteoporosis Intervention Trial protocol number 4 participated in this study. ONJ was diagnosed by experienced dentists. Suspected Stage 0 and 1 (bone exposure of the jaw) ONJ was assessed by a structured questionnaire at baseline and at 6, 12, 18, and 24 months. No established ONJ cases were diagnosed during the study. The incidence of suspected Stage 0 and/or Stage 1 ONJ was 6.14 per 1000 patient-years in the minodronic acid group and 3.38 per 1000 patient-years in the raloxifene group [hazard ratio (95% confidence interval) = 1.82 (0.84–3.93), P = 0.13]. Approximately 50–60% of bone exposures that appeared during the study had disappeared at the next observation. Although the subjects in this study may have developed a greater interest in the health of the oral cavity, the incidence of ONJ after minodronic acid treatment would be lower than the expected incident rate.

Keywords

Osteonecrosis Jaw Osteoporosis Antiresorptives Bone exposure 

Notes

Acknowledgements

The authors express their thanks to the chairman, Dr Rikushi Morita, and the members of the ethics committee, Ms Mamiko Matsumura, Dr Tetsuro Inoue, Dr Isao Yoshimura, Dr Mitsuyoshi Nakajima, Tooru Ebihara RPh, and Mr Shinya Hattori. The authors would also like to thank those who participated as clinical investigators in JOINT-04. This JOINT study was sponsored by the Public Health Research Foundation. This study was also supported in part by funding from the Project Promoting Clinical Trials for Development of New Drugs (17lk0201061h0002) from the AMED (Japan Agency for Medical Research and Development) to ST. We thank Helen Jeays, BDSc AE, from Edanz Group (www.edanzediting.com/ac) for editing a draft of this manuscript.

Compliance with ethical standards

Conflict of interest

AT received consultancy or lecture fees from Asahikasei Pharmaceutical Co., Teijin Pharma, Ono Pharmaceutical Co., Chugai Pharmaceutical Co., Takeda Pharmaceutical Co., and Daiichi Sankyo Co. YU received a consultancy fee from Teijin Pharma. ST has received lecture fees from Astra-Zeneca, Taiho, and Ono Pharmaceutical Co. He has received consultation fees from DeNA Life Science and CanBus. He has received outsourcing fees from Satt and Asahi Kasei Pharma. His wife has been engaged in a research project for Bayer. HO received fees from Pfizer Japan Inc. TS has received research grants from Astellas Pharma, Eisai, Daiichi Sankyo, Chugai Pharmaceutical, and Eli Lilly Japan as well as consulting and/or lecture fees from Asahi Kasei Pharma and Daiichi Sankyo. SS received lecture and consultancy fees from Asahikasei Pharmaceutical Co., Astellas Pharma, Chugai Pharmaceutical Co., Daiichi Sankyo Co., Eisai Co., Eli Lilly Japan, Ono Pharmaceutical Co., Pfizer Co., and Takeda Pharmaceutical Co. MS received lecture and consultancy fees from Asahikasei Pharma and Teijin Pharma. TI, TN, and HO declare that they have no conflict of interest.

Human and animal rights

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.

Informed consent

Informed consent was obtained from all individual participants included in the study.

References

  1. 1.
    Marx RE (2003) Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic. J Oral Maxillofac Surg 61:1115–1117CrossRefGoogle Scholar
  2. 2.
    Ruggiero SL, Mehrotra B, Rosenberg TJ, Engroff SL (2004) Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases. J Oral Maxillofac Surg 62:527–534CrossRefGoogle Scholar
  3. 3.
    Khan AA, Morrison A, Hanley DA, Felsenberg D, McCauley LK et al (2015) Diagnosis and management of osteonecrosis of the jaw: a systematic review and international consensus. J Bone Miner Res 30:3–23CrossRefGoogle Scholar
  4. 4.
    Marx RE, Sawatari Y, Fortin M, Broumand V (2005) Bisphosphonate-induced exposed bone (osteonecrosis/osteopetrosis) of the jaws: risk factors, recognition, prevention, and treatment. J Oral Maxillofac Surg 63:1567–1575CrossRefGoogle Scholar
  5. 5.
    Papapoulos S, Chapurlat R, Libanati C, Brandi ML, Brown JP et al (2012) Five years of denosumab exposure in women with postmenopausal osteoporosis: results from the first two years of the FREEDOM extension. J Bone Miner Res 27:694–701CrossRefGoogle Scholar
  6. 6.
    Yoneda T, Hagino H, Sugimoto T, Ohta H, Takahashi S, Soen S, Taguchi A, Toyosawa S, Nagata T, Urade M (2010) Bisphosphonate-related osteonecrosis of the jaw: position paper from the Allied Task Force Committee of Japanese Society for Bone and Mineral Research, Japan Osteoporosis Society, Japanese Society of Periodontology, Japanese Society for Oral and Maxillofacial Radiology, and Japanese Society of Oral and Maxillofacial Surgeons. J Bone Miner Metab 28:365–383CrossRefGoogle Scholar
  7. 7.
    Ruggiero SL, Dodson TB, Assael LA, Landesberg R, Marx RE, Mehrotra B, American Association of Oral and Maxillofacial Surgeons (2009) American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaws—2009 update. J Oral Maxillofac Surg 67:2–12CrossRefGoogle Scholar
  8. 8.
    Sumi E, Yamazaki T, Tanaka S, Yamamoto K, Nakayama T, Bessho K, Yokode M (2014) The increase in prescriptions of bisphosphonates and the incidence proportion of osteonecrosis of the jaw after risk communication activities in Japan: a hospital-based cohort study. Pharmacoepidemiol Drug Saf 23:398–405CrossRefGoogle Scholar
  9. 9.
    Shibahara T, Morikawa T, Yago K, Kishimoto H, Imai Y, Kurita K (2018) National survey on bisphosphonate-related osteonecrosis of the jaws in Japan. J Oral Maxillofac Surg 76:2105–2112CrossRefGoogle Scholar
  10. 10.
    Taguchi A, Shiraki M, Sugimoto T, Ohta H, Soen S, Japan Osteoporosis Society (2016) Lack of cooperation between physicians and dentists during osteoporosis treatment may increase fractures and osteonecrosis of the jaw. Curr Med Res Opin 32:1261–1268CrossRefGoogle Scholar
  11. 11.
    Ruggiero SL, Dodson TB, Fantasia J, Goodday R, Aghaloo T, Mehrotra B, O’Ryan F, American Association of Oral and Maxillofacial Surgeons (2014) American Association of Oral and Maxillofacial Surgeons position paper on medication-related osteonecrosis of the jaw—2014 update. J Oral Maxillofac Surg 72:1938–1956CrossRefGoogle Scholar
  12. 12.
    Matsumoto T, Hagino H, Shiraki M, Fukunaga M, Nakano T, Takaoka K, Morii H, Ohashi Y, Nakamura T (2009) Effect of daily oral minodronate on vertebral fractures in Japanese postmenopausal women with established osteoporosis: a randomized placebo-controlled double-blind study. Osteoporos Int 20:1429–1437CrossRefGoogle Scholar
  13. 13.
    Ettinger B, Black DM, Mitlak BH, Knickerbocker RK, Nickelsen T, Genant HK, Christiansen C, Delmas PD, Zanchetta JR, Stakkestad J, Gluer GC, Krueger K, Cohen FJ, Eckert S, Ensrud KE, Avioli LV, Lips P, Cummings SR (1999) Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. JAMA 282:637–645CrossRefGoogle Scholar
  14. 14.
    Fujiwara S, Miyauchi A, Hamaya E, Nicholls RJ, Weston A, Baidya S, Pinto L, Barron R, Takada J (2018) Treatment patterns in patients with osteoporosis at high risk of fracture in Japan: retrospective chart review. Arch Osteoporos 13:34CrossRefGoogle Scholar
  15. 15.
    Uemura Y, Tanaka S, Miyazaki T, Tsukiyama M, Sone T, Taguchi A, Soen S, Mori S, Hagino H, Sugimoto T, Fukunaga M, Ohta H, Nakamura T, Orimo H, Shiraki M, Adequate Treatment of Osteoporosis (A-TOP) research group (2018) Study design of multi-center, open-label randomized controlled, head-to-head trial comparing minodronic acid and raloxifene: japanese Osteoporosis Intervention Trial (JOINT)-04. J Bone Miner Metab.  https://doi.org/10.1007/s00774-018-0942-z (Epub ahead of print) Google Scholar
  16. 16.
    Japanese Allied Committee on Osteonecrosis of the Jaw, Yoneda T, Hagino H, Sugimoto T, Ohta H, Takahashi S, Soen S, Taguchi A, Nagata T, Urade M, Shibahara T, Toyosawa S (2017) Antiresorptive agent-related osteonecrosis of the jaw: position paper 2017 of the Japanese Allied Committee on Osteonecrosis of the Jaw. J Bone Miner Metab 35:6–19CrossRefGoogle Scholar
  17. 17.
    Nakamura M, Umetsu R, Abe J, Matsui T, Ueda N, Kato Y, Sasaoka S, Tahara K, Takeuchi H, Kinosada Y (2015) Analysis of the time-to-onset of osteonecrosis of jaw with bisphosphonate treatment using the data from a spontaneous reporting system of adverse drug events. J Pharm Health Care Sci 1:34CrossRefGoogle Scholar
  18. 18.
    Hasegawa T, Kawakita A, Ueda N, Funahara R, Tachibana A, Kobayashi M, Kondou E, Takeda D, Kojima Y, Sato S, Yanamoto S, Komatsubara H, Umeda M, Kirita T, Kurita H, Shibuya Y, Komori T, Japanese Study Group of Cooperative Dentistry with Medicine (JCDM) (2017) A multicenter retrospective study of the risk factors associated with medication-related osteonecrosis of the jaw after tooth extraction in patients receiving oral bisphosphonate therapy: can primary wound closure and a drug holiday really prevent MRONJ? Osteoporos Int 28:2465–2473CrossRefGoogle Scholar
  19. 19.
    Bedogni A, Fedele S, Bedogni G, Scoletta M, Favia G et al (2014) Staging of osteonecrosis of the jaw requires computed tomography for accurate definition of the extent of bony disease. Br J Oral Maxillofac Surg 52:603–608CrossRefGoogle Scholar
  20. 20.
    Kwon JW, Park EJ, Jung SY, Sohn HS, Ryu H, Suh HS (2015) A large National Cohort Study of the association between bisphosphonates and osteonecrosis of the jaw in patients with osteoporosis: a nested case-control study. J Dent Res 94:212S–219SCrossRefGoogle Scholar
  21. 21.
    Mücke T, Deppe H, Hein J, Wolff KD, Mitchell DA, Kesting MR, Retz M, Gschwend JE, Thalgott M (2016) Prevention of bisphosphonate-related osteonecrosis of the jaws in patients with prostate cancer treated with zoledronic acid—a prospective study over 6 years. J Craniomaxillofac Surg 44:1689–1693CrossRefGoogle Scholar
  22. 22.
    Owosho AA, Liang STY, Sax AZ, Wu K, Yom SK, Huryn JM, Estilo CL (2018) Medication-related osteonecrosis of the jaw: an update on the Memorial Sloan Kettering Cancer Center experience and the role of premedication dental evaluation in prevention. Oral Surg Oral Med Oral Pathol Oral Radiol 125:440–445CrossRefGoogle Scholar
  23. 23.
    Eiken PA, Prieto-Alhambra D, Eastell R, Abrahamsen B (2017) Surgically treated osteonecrosis and osteomyelitis of the jaw and oral cavity in patients highly adherent to alendronate treatment: a nationwide user-only cohort study including over 60,000 alendronate users. Osteoporos Int 28:2921–2928CrossRefGoogle Scholar
  24. 24.
    Chiu WY, Yang WS, Chien JY, Lee JJ, Tsai KS (2018) The influence of alendronate and tooth extraction on the incidence of osteonecrosis of the jaw among osteoporotic subjects. PLoS One 13:e0196419CrossRefGoogle Scholar

Copyright information

© Springer Japan KK, part of Springer Nature 2019

Authors and Affiliations

  • Akira Taguchi
    • 1
    • 10
    Email author
  • Yukari Uemura
    • 2
  • Takumi Imai
    • 3
  • Shiro Tanaka
    • 3
  • Hiroaki Ohta
    • 4
  • Toshitaka Nakamura
    • 5
  • Hajime Orimo
    • 6
  • Toshitsugu Sugimoto
    • 7
  • Satoshi Soen
    • 8
  • Masataka Shiraki
    • 9
  • Adequate Treatment of Osteoporosis (A-TOP) research group
  1. 1.Department of Oral and Maxillofacial Radiology, School of DentistryMatsumoto Dental UniversityShiojiriJapan
  2. 2.Biostatistics Division, Central Coordinating Unit, Clinical Research Support CenterThe University of Tokyo HospitalTokyoJapan
  3. 3.Department of Clinical Biostatistics/Clinical Biostatistics Course, Graduate School of MedicineKyoto UniversityKyotoJapan
  4. 4.Clinical Medical Research CenterInternational University of Health and Welfare, Women’s Medical Center, Sanno Medical CenterTokyoJapan
  5. 5.Touto Sangenjaya Rehabilitation HospitalTokyoJapan
  6. 6.Japan Osteoporosis FoundationTokyoJapan
  7. 7.Internal Medicine 1Shimane University Faculty of MedicineIzumoJapan
  8. 8.Department of Orthopaedic Surgery and RheumatologyKindai University Nara HospitalIkomaJapan
  9. 9.Department of Internal MedicineResearch Institute and Practice for Involutional DiseasesAzuminoJapan
  10. 10.Department of Hard Tissue Research, Graduate School of Oral MedicineMatsumoto Dental UniversityShiojiriJapan

Personalised recommendations